Selective Melanotropin Ligands for Neurodegenerative Diseases including Parkinson's

Case ID:

This technology involves administering an α-melanocyte-stimulating hormone through a carrier to selective melanotropin receptor ligands to treat neurodegenerative diseases. Specifically, this technology allows melanotropin to be administered through either one or both, the melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R).



There is a significant need for therapeutics to treat neurodegenerative disorders. In particular, Alzheimer’s disease afflicts more than 46 million people every year at substantial healthcare burden. In 2016, the cost in the US alone was $200B. Prevalence and cost are expected to continue to rise. 



  • Treatment of neurodegenerative diseases 


  • Able to cross the blood-brain barrier
  • Anti-inflammatory
  • Improved selectivity
Patent Information:
Contact For More Information:
Laura Silva
Sr. Licensing Manager, COS
The University of Arizona
Lead Inventor(s):
Minying Cai
Victor Hruby